Amydis Diagnostics, Inc. is a preclinical stage, privately-held pharmaceutical company founded in 2013 that is developing proprietary chemistry licensed out of UCSD using innovative approaches to detection of amyloid-related disorders. The Company’s lead program is addressing an important problem in today’s society regarding the clinical need for diagnostic testing of Alzheimer’s disease in its early stages.